Every year, PwC’s Health Research Institute names the top issues that will shape the US health industry in the year to come.
In this recorded quarterly webcast focusing on emerging accounting developments affecting not-for-profit organizations, we cover recent FASB standard setting developments that have occurred since our January webcast.
In this edition of Rx Marketplace Quarterly, we discuss the most recent quarter's industry IPOs, venture capital funding, and M&A activity. We also provide regulatory updates and cover financial reporting hot topics, including the new leasing standard and proposed amendments to the new revenue recognition standard.
2015 presented continued increases in deal volume across the vast majority of sectors when compared to 2014. Almost every sector experienced growth in either value or volume in transactions especially the healthcare sector.
The pharmaceutical and life sciences (PLS) industry saw extraordinary deal activity in 2015. A record total closed deal value for 2015 was $402.9 billion, far exceeding the $169.3 billion in 2014.
In this webcast replay, our tax specialists discuss the increase in merger and acquisition activities and various compensation and pension planning considerations which should not be overlooked by tax-exempt entities.
In this recorded webcast, PwC subject matter experts discuss recent developments and considerations around the OECD’s proposed Country by Country reporting requirements.
FASB’s new leasing guidance requires lessees to record leases embedded in other arrangements on their balance sheets.
This paper focuses on a key pillar of EHR controls optimization: the use of advanced analytics for pre-live testing and post-live monitoring to decrease an organization’s levels of exposure to financial, clinical, system integration, and compliance risks.
US venture capital funding for the life sciences sector, which includes biotechnology and medical devices, declined 27% by value and 15% by volume, on a year-over-year basis during the fourth quarter of 2015.